Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$22.71
+3.1%
$26.28
$19.16
$48.25
$1.07B1.26754,768 shs1.16 million shs
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
$0.96
+1.3%
$1.00
$0.58
$1.31
$278.10M0.096,132 shs2,868 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
+1.3%
$1.29
$0.98
$1.60
$1.13B1.52.86 million shs1.89 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$15.76
+4.9%
$17.04
$9.98
$29.65
$1.03B1.582.58 million shs2.30 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+3.04%+7.25%-2.15%-35.45%-25.73%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
+1.30%-0.51%-4.95%-6.80%+62.82%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.34%+6.34%+17.05%+34.82%+18.90%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+4.93%+3.01%+8.39%-24.95%-18.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$22.71
+3.1%
$26.28
$19.16
$48.25
$1.07B1.26754,768 shs1.16 million shs
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
$0.96
+1.3%
$1.00
$0.58
$1.31
$278.10M0.096,132 shs2,868 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
+1.3%
$1.29
$0.98
$1.60
$1.13B1.52.86 million shs1.89 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$15.76
+4.9%
$17.04
$9.98
$29.65
$1.03B1.582.58 million shs2.30 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+3.04%+7.25%-2.15%-35.45%-25.73%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
+1.30%-0.51%-4.95%-6.80%+62.82%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+1.34%+6.34%+17.05%+34.82%+18.90%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+4.93%+3.01%+8.39%-24.95%-18.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.75
Moderate Buy$44.1794.47% Upside
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.552.65% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.45
Hold$29.1384.80% Upside

Current Analyst Ratings Breakdown

Latest EDTXF, OPK, TNDM, and AORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Initiated CoverageBuyHold$15.50
6/16/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingBuy$36.00
6/11/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
DowngradeSell (D-)Sell (E+)
6/10/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
DowngradeStrong-BuyHold
6/8/2026
Artivion, Inc. stock logo
AORT
Artivion
DowngradeHold (C-)Sell (D+)
6/1/2026
Artivion, Inc. stock logo
AORT
Artivion
Set Price Target$45.00
6/1/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
UpgradeBuyOverweight$21.00 ➝ $27.00
5/28/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Reiterated RatingNeutral$22.00 ➝ $17.00
5/27/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Set Price Target$21.00
5/26/2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
UpgradeSell (E+)Sell (D-)
5/20/2026
Artivion, Inc. stock logo
AORT
Artivion
Reiterated RatingHold (C-)
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$441.33M2.50$1.14 per share19.99$9.46 per share2.40
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
$1.75M160.97N/AN/A($0.17) per share-5.65
OPKO Health, Inc. stock logo
OPK
OPKO Health
$581.12M1.96N/AN/A$1.67 per share0.90
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$1.01B1.06N/AN/A$2.29 per share6.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
$9.77M$0.2494.6330.28N/A2.55%7.15%3.63%8/6/2026 (Estimated)
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
-$34.13M-$0.10N/AN/AN/A-1,378.12%N/A-627.93%8/7/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$204.71M-$1.40N/A394.00N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)

Latest EDTXF, OPK, TNDM, and AORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
-$0.0072-$0.01-$0.0028-$0.01$0.54 million$0.64 million
5/7/2026Q1 2026
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
3/26/2026Q4 2025
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
-$0.0073-$0.0073N/A-$0.01$0.54 million$0.28 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.48
3.86
2.80
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/A
0.06
0.05
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.54
3.58
3.07

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
6.30%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
1.50%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,80048.54 million45.49 millionOptionable
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
29293.44 million289.04 millionNot Optionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,50068.53 million67.09 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$22.71 +0.68 (+3.09%)
Closing price 06/25/2026 03:59 PM Eastern
Extended Trading
$22.56 -0.15 (-0.64%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Spectral Diagnostics stock logo

Spectral Diagnostics OTCMKTS:EDTXF

$0.96 +0.01 (+1.30%)
As of 06/25/2026 12:46 PM Eastern

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.51 +0.02 (+1.34%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$1.51 0.00 (0.00%)
As of 07:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$15.76 +0.74 (+4.93%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$15.83 +0.07 (+0.44%)
As of 07:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.